HomeAI · summaries
Storia in 3 fonti
Hetero partners with Richter to develop, market Semaglutide injection globally
Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Gedeon Richter, Hetero Labs ink global pact for Semaglutide injection
Gedeon Richter and Hetero Labs form a global partnership to develop and commercialize Semaglutide Injection, enhancing diabetes treatment access.
- ·
economictimes.indiatimes.com
Hetero partners with Richter to develop, market Semaglutide injection globally
Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to…
